New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

LIBTAYO (cemiplimab-rwlc) injection. FDA-Approved. To treat CSCC

This specialty medication is authorized and manufactured internationally and is not registered or commercially distributed for retail sale in India. To verify patient eligibility, check international supply availability, or understand the regulatory logistics and documentation process: Call our Compliance Desk at 9891296838 or Email your Inquiry query@southdelhipharma.com.

LIBTAYO (cemiplimab-rwlc) injection is a prescription medicine. LIBTAYO (cemiplimab-rwlc) injection is used to treat metastatic cutaneous squamous cell carcinoma (CSCC).
INDICATIONS AND USAGE
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
DOSAGE FORMS & STRENGTHS: Injection: 350 mg/7 mL (50 mg/mL) solution in a single-dose vial.
Manufactured By: Regeneron
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “LIBTAYO (cemiplimab-rwlc) FDA Approved” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Categories ,
Categories ,

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

South Delhi Pharma is dedicated to facilitating access to critical, globally approved pharmaceutical therapies tailored to individual patient needs. Established in 1996, It has built a trusted reputation for assisting patients and healthcare institutions in navigating the regulatory frameworks required to securely source high-quality, international life-saving medications.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

This is an inquiry and facilitation request form. Submission does not constitute a sale, purchase order, or guarantee of medicine availability.

Description

Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.

The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.

In September 2018, it was approved by the U.S. Food and Drug Administration (FDA) for treating people with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. It was approved for medical use in the European Union in June 2019. It was approved for medical use in Australia in July 2020.

Cemiplimab is the first FDA approval of a medication specifically for advanced cutaneous squamous cell carcinoma (CSCC).

Related Products